EU approves Wyeth's improved hemophilia B drug

08/21/2007 | In-PharmaTechnologist.com

The European Union approved a new version of Wyeth's hemophilia B drug BeneFix. The improved product contains a lower diluent volume for all dosage strengths, comes in a prefilled syringe, has a bigger IU vial and features a needle-less reconstitution device. Wyeth hopes these changes will make the treatment easier for patients to prepare and use.

View Full Article in:

In-PharmaTechnologist.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Regulatory Counsel
Food and Drug Administration
Silver Spring, MD
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Vice President, Commercial Markets
Meridian Health
Neptune, NJ
Health Plan CEO – Oregon
Trillium Community Health Plan
Eugene, OR
Director of Operations - GBS
Mayo Clinic
Rochester, MN